» Articles » PMID: 3025209

Short-term Feedback Regulation of CAMP by Accelerated Degradation in Rat Tissues

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1987 Jan 5
PMID 3025209
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A recent study showed that cAMP analogs lowered cAMP levels in rat hepatocytes (Corbin, J.D., Beebe, S.J., and Blackmore, P.F. (1985) J. Biol. Chem. 260, 8731-8735). The present work demonstrates that cAMP analogs also lowered cAMP in a rapid, concentration-dependent manner in heart and fat cells. In order to determine if the cAMP-dependent protein kinase mediated this effect, techniques were developed to assay the protein kinase activity ratio in hepatocytes treated with cAMP analogs. The activation of protein kinase and phosphorylase in hepatocytes by 8-pCl phi S-cAMP (where 8-pCl phi S- indicates 8-parachlorothiophenyl-) was concentration-dependent and occurred in parallel to proportionate decreases in cAMP. More than 20% of the cAMP binding sites on the protein kinase were unoccupied at concentrations of 8-pCl phi S-cAMP that produced maximal cAMP lowering. Thus, the possibility that 8-pCl phi S-cAMP lowered cAMP by displacing it from protein kinase binding sites, making it available for hydrolysis, seemed unlikely. In adipocytes, the lowering of cAMP by 8-pCl phi S-cAMP occurred in parallel with increases in lipolysis and activation of low Km phosphodiesterase, suggesting that the phosphodiesterase was responsible for the cAMP lowering. Further evidence for this assertion was the finding that in hepatocytes preloaded with low concentrations of 8-pCl phi S-cAMP, glucagon lowered 8-pCl phi S-cAMP by about 50%, an amount similar to the cAMP lowering observed with 8-pCl phi S-cAMP treatment. The results were consistent with a cAMP-dependent protein kinase-catalyzed activation of a phosphodiesterase and suggested that 8-pCl phi S-cAMP-mediated hydrolysis of cAMP mimicked a physiologically significant response. The observation of this phenomenon in several tissues further suggested that it may be a general mechanism for dampening and terminating the hormonal signal through accelerated degradation of cAMP.

Citing Articles

Effect of beta-agonists on LAM progression and treatment.

Le K, Steagall W, Stylianou M, Pacheco-Rodriguez G, Darling T, Vaughan M Proc Natl Acad Sci U S A. 2018; 115(5):E944-E953.

PMID: 29339522 PMC: 5798385. DOI: 10.1073/pnas.1719960115.


Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.

Molenaar P, Christ T, Berk E, Engel A, Gillette K, Galindo-Tovar A Naunyn Schmiedebergs Arch Pharmacol. 2014; 387(7):629-40.

PMID: 24668024 DOI: 10.1007/s00210-014-0974-4.


PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.

Molenaar P, Christ T, Hussain R, Engel A, Berk E, Gillette K Br J Pharmacol. 2013; 169(3):528-38.

PMID: 23489141 PMC: 3682702. DOI: 10.1111/bph.12167.


Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Kaumann A, Galindo-Tovar A, Escudero E, Vargas M Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(5):421-30.

PMID: 19693491 DOI: 10.1007/s00210-009-0445-5.


Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors.

Galindo-Tovar A, Vargas M, Escudero E, Kaumann A Br J Pharmacol. 2009; 156(2):237-49.

PMID: 19154438 PMC: 2697829. DOI: 10.1111/j.1476-5381.2008.00023.x.